The RSPB has reported the results of two studies which revealed that a greater diversity of birds of prey, including some eagles, are killed eating carrion contaminated with diclofenac.
The RSPB says that these findings strengthen the case of banning the use of veterinary diclofenac in livestock across Europe, including Spain and Italy where the drug has already been approved.
In the first paper1, published in the journal Bird Conservation International, scientists present results of tests carried out on two steppe eagles found dead at a cattle carcass dump in Rajasthan, India. Both birds had diclofenac residue in their tissues and exhibited the same clinical signs of kidney failure as seen in Gyps vultures experimentally given diclofenac.
Steppe eagles are closely related to the golden eagles found in the UK, the vulnerable Spanish imperial eagle and other globally vulnerable or declining Eurasian eagles. Scientists now fear that all species in this genus, known as Aquila, are susceptible to diclofenac. With fourteen species of Aquila eagle distributed across Asia, Africa, Australia, Europe and North America, this means that diclofenac poisoning should now be considered largely a global problem.
Dr Toby Galligan, RSPB conservation scientist and one of the authors of the paper, said: "We have known for some time that diclofenac is toxic to Gyps vultures, including the Eurasian griffon vulture, but we now know it is toxic to an Aquila eagle too. This suggests that the drug is fatal to a greater number of birds of prey in Asia, Europe and around the world. We had suspected as much from observed declines in non-Gyps vultures in Asia, but this study confirms our worst fears."
In another paper2, published in Bird Conservation International, Dr Galligan led an examination of recent population trends in Egyptian and red-headed vultures in India. That study shows population declines of similar timing and scale as the declines observed in Gyps vultures, providing indirect evidence that these species have been impacted by diclofenac as well.
After years of campaigning by conservationists, the governments of Bangladesh, India, Nepal, and Pakistan banned veterinary formulations of diclofenac between 2006 and 2010. Recently, experts have recorded a slowing of Gyps vulture declines as a result of the bans. However, formulations of diclofenac intended for use in humans are still widely available and illegally used to treat livestock, the carcasses of which are the main food source for vultures in South Asia. It was announced in March that veterinary diclofenac had been authorised for manufacture and use in Italy and Spain and had been distributed to other European countries. Since then, a coalition of organisations including the Vulture Conservation Foundation, the RSPB and BirdLife International have been campaigning for this decision to be reversed.
Dr Galligan continued: "In light of recent developments in Europe, our findings take on an even more worrying meaning. All of Europe's charismatic Aquila eagles, like the Spanish imperial eagle and, closer to home, the golden eagle, are opportunistic scavengers and therefore could be at risk of diclofenac poisoning. As we have seen in South Asia, wherever free-ranging livestock are treated with diclofenac, population declines in vultures and eagles can occur. The European Commission needs to recognise this problem and impose a continent-wide ban on veterinary diclofenac before it can impact on our birds."
Last week, the Veterinary Medicines Directorate (VMD) announced measures against the drug.
In a statement the VMD said: "The UK's Veterinary Medicines Directorate is taking the issue of diclofenac's risks to vulture populations seriously. As a precautionary measure the VMD will not approve any requests from vets to import products containing diclofenac. Furthermore, the VMD has agreed not to issue any export certificates which name diclofenac-containing products in the list of products to be exported."
Sacha Cleminson, Head of International Biodiversity Policy at the RSPB, said: "The announcement from the Veterinary Medicines Directorate is a welcome signal to Europe that the UK is taking the issue seriously. This new evidence underlines the need for a ban across Europe, and ultimately beyond."
References
Have population declines in Egyptian Vulture and Red-headed Vulture in India slowed since the 2006 ban on veterinary diclofenac? Toby H. Galligan et al. Bird Conservation International Online. 1st April 2014.
The President of the British Veterinary Association has written to the Badger Trust to clarify the BVA position on the pilot badger culls in England, stating that it will not be supporting the Trust's application for a judicial review.
The BVA Council agreed a position on the continuation of controlled shooting in the pilot areas on 16 April. The position states that the BVA could only support further culling using controlled shooting in the pilot areas if steps are taken to improve both its effectiveness and humaneness and if there is robust monitoring and collation of results and independent analysis and auditing by a non-governmental body. It also states that the BVA supports the Independent Expert Panel's (IEP) recommendations for improving effectiveness and humaneness and urges Defra to implement all the IEP's recommendations fully.
The BVA says that since 16 April, it has been in dialogue with Defra to seek assurances that these issues will be addressed, and those discussions are ongoing. It will not be taking a further position on the pilot culls until BVA Council has had the opportunity to consider Defra's plans in full, when they are made available.
In a press release dated 20th May, The Badger Trust CEO Dominic Dyer said: "It is not acceptable for the DEFRA Secretary of State to now push aside the concerns of both the Independent Expert Panel and the British Veterinary Association, by moving ahead with a further badger cull in Gloucestershire and Somerset this summer without any independent monitoring in place."
The BVA says it is concerned that this misrepresents its position, and has led to some media reports suggesting that the BVA has withdrawn its support for badger culling as part of the overall strategy to eradicate bovine TB. It has not. The BVA says it continues to believe that the TB eradication strategy for England will only be successful if we are able to use all of the available tools, including targeted, humane badger culling.
The Westpoint Veterinary Group and Eville & Jones, a veterinary control provider, have joined forces to form Xperior Farm Health, which will bid for appointment as a Delivery Partner for bovine TB and other farm animal disease testing under AHVLA's Veterinary Delivery Partnership Programme.
The Delivery Partnership Programme, under which the AHVLA will cease to contract OVs directly and instead procure disease testing services from around ten Delivery Partners, is expected to roll out in the summer.
Eville & Jones is an experienced service provider in inspection and testing services in the fields of animal health, public health and animal welfare. The company employs more than 450 veterinary staff nationwide and already provides fully managed Official Veterinarian (OV) services to UK Competent Authorities.
Westpoint Veterinary Group is a specialist, farm-animal-only veterinary practice operating from 17 sites countrywide to provide farmers with specialist and locally based services. It is the largest veterinary group in the UK specialising in production animals, employing more than 50 veterinary surgeons.
Veterinary Director Phil Elkins MRCVS says the resources and experience of the two parent companies in both farmer-facing and back office dimensions make Xperior Farm Health well equipped to fulfil a Delivery Partner service expected by AHVLA. He said: "Our ambition is to provide an exemplary standard of accurate and trustworthy on-farm animal health testing services, where possible using subcontracted practices. If appointed, of course, these will be farmer friendly, provide an ongoing source of work and revenue to subcontractor Official Veterinarians, and represent excellent value for money to the taxpayer."
Registered VN Lindsay Newell has been found guilty of six counts of cruelty to animals at Stafford Magistrates' Court, following an investigation by the RSPCA.
The charges related to a ewe, two lambs, a Welsh pony, a goat and a pig at the Burton Wildlife and Animal Rescue Centre, a sanctuary founded in 2008 by the 27-year-old nurse in memory of her murdered grandparents.
The pig had made headlines in the Daily Mail in 2012 when Newell rescued it from a Derby council house.
Newell was given a 2-year conditional discharge, ordered to pay £2000 in costs, and disqualified from keeping sheep, equines, goats or pigs for five years.
Passing sentence, district judge David Taylor said: "These were not deliberate or intentional acts. They were a consequence of you trying to take on too many animals of a wide range."
Newell was cleared of 25 other charges of failing to feed the animals in her care properly.
RSPCA inspector Jayne Bashford who led the investigation said: "We are satisfied that the court has found the defendant guilty of six charges of unnecessary suffering. The scene the RSPCA discovered when they visited with Police, Derbyshire Trading Standards and an independent vet were quite shocking.
"This was an extremely disturbing case where there was clear neglect and mistreatment of animals by a registered veterinary nurse.
"I am sure she set up this centre with the best intentions but things got totally out of control."
More on this story
Novartis Animal Health has announced the launch of Strenzen, an oral water medication for pigs, indicated for the treatment of gastrointestinal infections caused by Escherichia coli, Clostridium perfringens and Salmonella Typhimurium, and for respiratory tract infections caused by Actinobacillus pleuropneumoniae, Pasteurella multocida and Streptococcus suis.
Strenzen contains contains a combination of amoxicillin trihydrate (500 mg/g) and potassium clavulanate (125 mg/g) in ratio of 4:1. Novartis says it is ideally suited for the treatment of post-weaning infections in pigs.
According to the company, the combination of amoxicillin and clavulanic acid broadens the performance of amoxicillin1,2, especially against resistant strains of bacteria capable of producing ß-lactamase enzymes. Certain bacteria are able to produce ß-lactamase enzymes as a protection mechanism, making the amoxicillin molecule ineffective against them. The clavulanic acid in Strenzen binds to the molecules of the ß-lactamase enzyme, ensuring the amoxicillin remains unaffected and free to attack bacteria. Prof. Dominiek Maes, DVM, MSc, MS, PhD, Dipl. ECVPH, Dipl. ECPHM, from the Porcine Health Management Unit of the Ghent University, Belgium said: "Weaning is a stressful event for piglets and there are several opportunistic diseases that can impact them during this period. The challenge with E. coli and S. suis infections is that in many countries there are currently no commercial vaccines available with proper efficacy. I believe Strenzen can indeed be very helpful in managing those infections which are so prevalent after weaning."
Novartis says Strenzen is rapidly excreted, leading to a withdrawal period of one day, which in turn maximizes production flexibility for pig producers. In addition, the water-soluble formulation of Strenzen ensures that treated pigs get a therapeutic dose even when they stop eating, making it an ideal treatment for sick pigs with compromised appetites.
Recent field trials on infected farms in Spain and the Czech Republic demonstrated that Strenzen-treated pigs give better production performance, better economic returns and require less medical intervention3,4,5. The reduction of the overall amount of antibiotics needed to treat severe post-weaning infections not only saves producers the costs of the labour and the medication, but is also important in regard to the development of resistance in bacteria.
Dr. Ulrich Klein, Global Technical Services Manager, Novartis Animal Health said: "With the launch of Strenzen, Novartis Animal Health demonstrates its commitment to continually broadening our product portfolio to address the specific needs of farmers and food producers. Strenzen has the ideal spectrum for the treatment of post-weaning infections, delivering better productivity results than current therapies for those infections."
Elanco Animal Health has announced that there have been extensions to the withdrawal periods for Dectomax (doramectin) 10 mg/ml Solution for Injection and Micotil (tilmicosin) 300 mg/ml Solution for Injection.
For Dectomax injectable, meat withdrawal for cattle and sheep will be extended to 70 days and pigs to 77 days. For Micotil, sheep milk withdrawal will be extended to 18 days and milk from cows during the dry period or from pregnant heifers should not be used for human consumption until 36 days after calving.
Elanco is reminding veterinary surgeons and SQPs that they may continue to prescribe according to the current label but it is good practice to implement revised withdrawal periods. The company is also taking this opportunity to highlight the importance of getting into the habit of double-checking withdrawal periods when administering drugs, because they do change from time to time in the light of new knowledge.
BVA president-elect John Blackwell has found himself on the front page of The Times today, and interviewed on Radio 4's Today programme, with a call to end the practice of slitting animal's throats and allowing them to bleed to death in order to produce kosher and halal meat.
According to the newspaper, 600,000 animals are killed this way every week in the UK.
Mr Blackwell is urging Jews and Muslims to allow meat-producing animals to be stunned before they are killed.
Speaking to The Times, Mr Blackwell said: "As veterinary surgeons, it is one of the most important issues on our radar. This is something that can be changed in an instant."
See other media reports here.
Novartis Animal Health has launched Farming against BVD, a new initiative to help in the fight against Bovine Viral Diarrhoea (BVD).
The campaign, which is being carried out in partnership with key industry bodies, will begin with an independent survey of farmers, the results of which will be announced in April.
An expert panel, headed by Professor Joe Brownlie (Royal Veterinary College and Chairman of the BVD Scientific and technical working group), will then come together to analyse the findings, using them to shape and drive an industry response.
Professor Brownlie said: "BVD is a costly and complex disease, spread by a pestivirus that affects the reproductive and immune systems. Persistently Infected (PI) animals are the main source of infection, but can be hard to identify without testing. Only total eradication will prevent the disease from spreading. Eradication Schemes in a number of European countries have already succeeded and Scotland and Ireland have embarked on similar schemes. The information being gathered will help the industry to develop a much needed scheme for England and Wales."
Joining Professor Joe Brownlie on the expert panel will be Dr Peter Nettleton (Moredun Research Institute), Mansel Raymond (dairy farmer and Chairman of the NFU Dairy Board), Caroline Dawson (Novartis Animal Health veterinary surgeon) and Paddy Gordon (veterinary practitioner).
Survey topics will include levels, and methods, of testing for BVD on farm, understanding of the role of PI animals and the financial impact of BVD on dairy and beef units. Farmers will also be asked who they look to for advice and how they view the role of vaccination.
Caroline Dawson MRCVS from Novartis Animal Health said: "Countrywide eradication may not be achieved for a number of years, although individual farmers can control the disease on their own farms within 1-2 years, providing substantial cost benefits. The purpose of this campaign is to encourage farmers to take action now against BVD. By working closely with their vets, identifying and removing PI animals, BVD can be removed. Ensuring adequate biosecurity and a robust vaccination policy will eliminate the risk of bringing BVD back onto the farm."
Professor Brownlie said: "Understanding what farmers understand about BVD, particularly the role of the PI animal, will enable members of the panel and the wider industry, including Novartis and the BVD Stakeholder Group, to meet farmer needs more accurately. Greater awareness of the problem is vital - this is the only way that progress towards eradication will be made."
Novartis Animal Health has launched 'The Wormer Decision Tree', an online tool to help veterinary surgeons in giving sheep farmers the most up-to-date advice about worming.
Lesley Stubbings, SCOPS representative and Independent Sheep Consultant said: “Choosing the right wormer group is hugely important and there remains much confusion especially when it comes to anthelmintic resistance.
“Worms, including resistant and multi-resistant species, are threatening the productivity of sheep farms. However with a well-thought-out worming strategy that uses both the new wormer groups, in association with existing wormers, it is possible to slow resistance.”
Results of the Farming Against Wormer Resistance (FAWR) campaign survey, conducted in 2013, revealed growing concern about wormer resistance among farmers - but confusion about the best course of action to take.
Fiona Anderson, Novartis Animal Health Veterinary Manager said: "This tool has been developed adhering to SCOPS principles and is designed to ensure a consistent responsible approach is used when prescribing anthelmintics.
"Available only to SQPs and vets, it will be a valuable tool to train new staff and use with farmers, to explain which of the five drench classes are appropriate for particular sheep groups at specific times of year."
The Novartis Wormer Decision Tree asks three key questions: the type of sheep being dosed, the purpose of the dose, and the farm's resistance status. It then produces a recommendation of the required active ingredient, along with more detailed information to support the recommendation. There is also a calculator which provides a dose rate and cost per dose based upon the recommendation.
To use the decision tree, you must first register on the Novartis Farm Animal Health website: www.farmanimalhealth.co.uk. Then head here: www.farmanimalhealth.co.uk/wormerdecisiontree
As the House of Lords begins its debate on the religious slaughter of farm animals, the RSPCA is calling for all to be pre-stunned.
More than 900 million farm animals are slaughtered for meat in the UK every year. The vast majority are stunned pre-slaughter. However, the law permits the Jewish and Muslim communities to kill animals by religious methods without any form of pre-stunning.
The RSPCA says that while it recognises that religious beliefs and practices should be respected, it also believes that animals should only be slaughtered under the most humane conditions.
RSPCA Dr Julia Wrathall, head of the RSPCA's farm animal science department said: "Farm animals deserve to be treated with care and respect throughout their lives, from the time they are born right up to their final moments in the abattoir.
"We want to see all animals rendered unconscious before slaughter. Until that time we are calling for clear labelling so shoppers are armed with information that can enable them to make an informed choice about whether they buy meat from animals which have not been stunned before slaughter.
"Until there is better, universal labelling, shoppers should look for the blue and white Freedom Food label. Meat produced under this RSPCA assurance scheme comes from animals inspected to the RSPCA's farm animal welfare standards which do not permit slaughter without pre-stunning."
According to the charity, scientific research shows that slaughtering animals without pre-stunning (to render them insensible to pain and distress) can cause unnecessary suffering.
David Bowles, head of public affairs for the RSPCA, who has written a report for the House of Lords debate, added: "We know this is a subject that our supporters feel passionately about. We share their welfare concerns and that is why we have continued to campaign for religious slaughter to be discussed at the highest possible levels."
The RSPCA works with the Food Standards Agency (FSA) to publish the results of the FSA's Animal Welfare Survey undertaken in abattoirs across Great Britain.
The latest survey* results shows:
The RSPCA believes mandatory labelling should be introduced so that all meat that has not been stunned is labelled and says it will press for European rules on this in 2014.
Zoetis has launched Suvaxyn Parvo/E, a combined vaccine which it says provides the earliest protection of gilts against parvovirus and erysipelas.
Parvovirus and erysipelas infections occur primarily in gilts and sows, negatively impacting their reproductive success and the health of their litters - inevitably reducing profitability.
Nigel Lodge, National Veterinary Manager for Zoetis, said: "The combined vaccine will help ensure the health of gilts and sows is not affected by these two infections which are widespread in the pig herd.
"Suvaxyn® Parvo/E gives the earliest protection so that the ability to vaccinate gilts at five months of age will help ensure a good start to their reproductive life. Up to half of all pigs may be carriers of erysipelas and importantly the vaccine has licensed efficacy against both Erysipelothrix serotypes 1 and 2.
"This brings another vaccine to our portfolio, making it one of the largest in the pig sector and confirming the ongoing commitment of Zoetis to the health and welfare of pigs."
Suvaxyn® Parvo/E is an inactivated combination vaccine approved for immunising gilts and sows to prevent reproductive disorders caused by porcine parvovirus and reduce clinical signs caused by Erysipelothrix rhusiopathiae.
Primary vaccination is recommended from five months of age, with two injections given three to four weeks apart, ensuring the second dose occurs at least four weeks before mating. Revaccination should take place three to four weeks before each subsequent mating.
The vaccine comes in 10-dose and 2 X 25-dose packs. For more information, contact your Zoetis Pig Key Account Manager.
Dechra Veterinary Products has launched Cyclo Spray, an antibiotic spray for veterinary professionals treating hard to reach sites when handling cattle, sheep and pigs.
Dechra says the new product has been developed for use at any angle, even upside down.
Cyclo Spray (chlortetracycline hydrochloride 2.45%) is indicated for the treatment of superficial claw and hoof infections and the prevention of infections of superficial traumatic or surgical wounds.
Dechra Veterinary Products Brand Manager Emma Jennings said: "Vets dealing with livestock can often find that they are twisting themselves into awkward positions to get to hard to reach sites with traditional spray can treatments. Not only are they having to find the right angle to ensure the can works, but also potentially the treatment can drip or take time to dry.
"We've introduced Cyclo Spray to our portfolio to help combat some of those difficulties - it is a new 360 degree spray can allowing users to mark the site of application with confidence from whatever angle. It is non-drip, fast-drying with excellent adhesive characteristics and contains a non-toxic colouring agent."
Cyclo Spray is available in 211ml and 422ml can sizes. No withdrawal days are required for meat and milk.
To promote the launch of the new product, Dechra has also launched a competition giving entrants the chance to win a two day trip to London for two people to ride the London Eye and experience the capital from a 360 degree vantage point.
To enter the competition, with the prize including return rail travel, and dinner, bed and breakfast in a 4* hotel, visit www.dechra.co.uk to download an entry form.
Bimeda UK has announced that Endofluke 100mg Oral Suspension has been approved for use in dairy cows, with a milk withdrawal period of 45 days + 48 hours.
Endofluke is licensed for use in cattle and sheep and its active ingredient, triclabendazole (100mg/ml) kills all three stages of liver fluke.
Bimeda UK Sales Manager, Andrew Lane said: "This is great news for the UK's dairy farmers. Endofluke has long been favoured by British & Northern Irish farmers as a liver fluke treatment, due to its ability to offer complete chronic and acute fluke control in both sheep and cattle. It is proven to be highly effective against early-immature, immature and adult liver fluke, and to now be able to extend these benefits to dairy cows, is fantastic news for the UK's dairy farmers."
Endofluke is a POM-VPS product.
For more information, visit www.bimeda.co.uk or contact Bimeda UK Sales Manager Andrew Lane, on alane@bimeda.com or on 07917 208524.
Bayer is highlighting a new study which, the company says, proves that a 'metaphylactic' treatment approach to coccidiosis - when the animal has been infected, but before the disease has had chance to take hold - produces the best long term results1.
The research spanned a two year period where heifer calves on two farms that had previously experienced problems with naturally acquired coccidiosis, were divided into two groups. One group was treated with Baycox and one group remained untreated. The calves were then monitored for two years to gather the long term results following the coccidiosis treatment.
Sharon Cooksey BVSc, MRCVS, Bayer Animal Health Group Product Manager said: "The results demonstrated that treatment with Baycox at the right time significantly reduced the average age to first service by 24 days in comparison with the non-treated control group.
"Other key long term benefits following treatment included positive effects on certain fertility parameters, including overall pregnancy rate, the first service conception rate and average services per conception as well as a significant reduction in oocyst shedding in the treatment group."
Sharon says the take home message of the new research is the paramount importance of getting treatment right at the right time, before coccidiosis develops and causes any long term implications: "The positive impact on heifer development from correct subclinical coccidiosis treatment is clear to see in this research, with the reduction of days to first service alone being a powerful reason for farmers to seek veterinary advice."
Reference
Bimeda has launched Recocam, a 20mg/ml meloxicam preparation licensed for use as a single injection course in cattle, horses and pigs.
Bimeda's Head of Technical Services, Padraig Hyland MVB said: "Meloxicam's anti-inflammatory credentials and safety profile is well proven and it remains rightly popular with large animal vets. With our manufacturing expertise it makes sense to add this widely used product to our portfolio. Our aim is to provide a comprehensive range of both established standards and new innovative products for cattle and equine vets, and this is just another step in that process."
Bimeda says Recocam has a broad range of indications including acute respiratory infections, in combination with oral re-hydration in diarrhoea therapy and acute mastitis, for non-infectious locomotor disorders and lameness in pigs and alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders and pain relief associated with equine colic. In cattle Recocam can be given by single subcutaneous or intravenous injection.
BCF Technology has published a new clinical guide to the non-reproductive applications of ultrasound in farm animals.
Kimberly Palgrave BS BVM&S, created the booklet with the aim of helping veterinary surgeons understand the value in using ultrasound for more than reproduction purposes.
BCF says On farm ultrasound uses: Beyond pregnancy diagnosis provides key clinical descriptions and tips, along with normal and abnormal ultrasound images to show how ultrasound can aid in diagnosing various on-farm conditions you may be presented with, such as scanning the teat to detect stenosis, the umbilical area for an abscess, and even the thorax for help to diagnose BRD.
Kimberly said: "This clinical guide was created to help vets get more out of on farm ultrasound than just pregnancy diagnosis. There are a range of other uses for ultrasound on farm and this guide explains how to use your equipment for these applications. As always we are happy to receive feedback on any of our clinical materials."
To find out more or to get your copy of the guide, visit the learning section of the BCF website: www.bcftechnology.com
Zoetis has announced that Suvaxyn MH-One, its vaccine against Mycoplasma hyopneumoniae in pigs, has a revised licence allowing it to be administered from seven days of age with a two-week onset of immunity.
The company says this means that piglets can be protected by three weeks of age when they are commonly already infected with M. hyo. Duration of immunity extends well beyond the average UK pig slaughter age of 176 days.
Nigel Lodge, National Veterinary Manager for Zoetis in the UK said: "This is a significant step forward, recognising the full efficacy of the Suvaxyn MH-One vaccine against enzootic pneumonia. Trials have confirmed that use of Suvaxyn MH-One at seven days reduces lung lesions - even in the presence of maternally derived antibodies.
"The vaccine, which adds to our large and growing pig vaccine and product portfolio, also benefits from using adjuvants carbopol and squalane."
According to the company, the performance gains from early protection are shown in a field trial with 240 pigs injected at one week of age which showed significantly higher average daily weight gain, providing nearly 5 kg extra weight over the study period to 166 days.
MSD Animal Health has announced a new claim for Bovilis BVD and Bovilis IBR Marker Live vaccines which means they can be mixed and administered in a single syringe.
MSD says the new mixing claim will offer significant advantages in herd health planning when controlling two of the more important infectious diseases in cattle.
Bovine Viral Diarrhoea (BVD) and Infectious Bovine Rhinotracheitis (IBR) remain major threats to cattle health and productivity. Vaccinations are commonly given at housing and/or turnout, which are both busy times for veterinary surgeons and on the farm in the herd health planning calendar.
The mixed vaccines are suitable only for booster vaccinations of animals from 15 months of age previously vaccinated separately with Bovilis IBR Marker Live and Bovilis BVD. The mixed vaccine needs to be used within three hours.
MSD says the mixing procedure is clear and easy, but there is an instructional video here: http://www.msd-animal-health.co.uk/Mixing_bovilis_BVD_Bovilis_IBR-Marker_Live.aspx
The University of Bristol's School of Veterinary Sciences at Langford has opened a £2 million state-of-the-art dairy farm.
Wyndhurst Farm's dairy unit has undergone a major rebuild in order to provide a world-class practical teaching environment for around 600 veterinary students, as well as a facility that can be used to support research and the continual professional development of veterinary surgeons, farmers and others involved in the dairy industry locally, nationally and internationally. Professor Jo Price, Head of the School of Veterinary Sciences, said: "This is an exciting time for the Vet School. The new dairy unit will enable our undergraduate and postgraduate students to be taught in a world-class facility. It will provide the best standards of animal welfare for our dairy herd and will support our research on the prevention and treatment of diseases of farm animals."The farm, which is approximately 250 acres, includes numerous features to ensure high welfare standards. The dairy herd will be housed in deep sand bedded cubicles, with parts of the floors covered in soft rubber to protect the cows' feet and when housed cows will be fed a total mixed ration using grass, maize and whole crop wheat silages grown on the farm.Since the new facility has been built the farm's herd of Pedigree Holstein cows have increased in number from 110 to 180 cows and will soon reach 200, with each cow giving over 9,000 litres of milk per year. The farm also has a newly established breeding flock of 100 New Zealand Romney ewes. Since 2010 it has been managed by Velcourt Farm Management.
Norbrook Laboratories has launched Noroseal, a new teat sealant containing a unique anti-infective ingredient.
The company says that Noroseal, a 2.6g intramammary suspension, is the only teat sealant in the market-place in Europe to contain a PVP-Iodine excipient.
Dr Barry McInerney MVB, MRCVS, PhD, Norbrook GB Veterinary Advisor said: "Noroseal, with its unique formulation, offers vets a proven barrier against intramammary infections during the dry period.
"New bacterial infections occur most often during the first three weeks of drying off because the cow's natural keratin plug is not completely formed. Indeed, approximately 50% of teat canals are still open for up to seven days after drying off. Noroseal Teat Sealant will mimic the cow's keratin teat barrier offering immediate protection against infection. Additionally, the anti-infective ingredient, PVP-Iodine, complements the effectiveness of the teat-sealant components in the teat canal barrier."
Norbrook says that the estimated annual cost of mastitis to the UK dairy industry is in excess of £168M with a single case of clinical mastitis costing farmers approximately £178.00 per cow.
Dr McInerney added: "Clinical mastitis is a costly business but one that can be avoided if timely action is taken. There are various treatments available for dealing with mastitis but studies have shown that the risk of clinical mastitis may be reduced by up to 50% by using a combination of teat sealant and dry cow intramammary therapy. Noroseal is therefore an ideal combination with Norbrook's dry cow therapies such as Noroclox DC, Bovaclox DC Xtra and Bovaclox DC."
Noroseal is available in packs of 24 or buckets of 120 units. A range of promotional material is also available to veterinary practices via the Norbrook Sales Team.
The National Office of Animal Health has released two films to help industry and consumers understand issues surrounding the use of animal medicines in the food chain.
A film made for the food chain industry titled "Animal Medicines in Food Production - The Food Industry Perspective" has been produced to help industry understand the levels of awareness and concerns that consumers have.
A second film, "Animal Medicines in Food Production - Challenging the Myths" is aimed at consumers and looks at some of the myths surrounding the use of animal medicines in livestock production.
Phil Sketchley, Chief Executive of NOAH, said that while the public was generally supportive of the use of animal medicines in farm production, there was a knowledge gap among consumers about the way that medicines were used: "It was interesting to discover how much people knew about medicines in food production. There were some very positive attitudes among consumers, particularly towards the way British farmers care for their animals. But there were still some areas of concern, for example with the belief among a large number of people that growth hormones were still being used on UK farms, despite the fact they have been banned since 1988.
"The industry film should help people involved in food production understand what consumers are thinking when it comes to animal medicines. Animal health and welfare and ensuring sick animals are treated is a big issue, and food producers and retailers need to be able to communicate clearly with consumers on the subject of animal medicines.
"It is important there is transparency on all issues of animal health and welfare."
MSD Animal Health has reintroduced Zanil, the flukicide drench for cattle and sheep.
Based on the active ingredient oxyclozanide, MSD says Zanil is highly effective against the adult fluke responsible for chronic disease and - significantly for dairy farmers - is licensed for use in young, pregnant and lactating animals, with a 72-hour milk withhold period where milk is produced for human consumption.
MSD Animal Health veterinary advisor Matt Haslam said: "The latest independent data1 confirms that fluke is on the increase in UK cattle and sheep. The fluke problem is longstanding, but is being exacerbated by recent wet summer and autumn periods that have created ideal conditions for this parasite to proliferate and infect grazing livestock.
"Chronic liver fluke causes serious economic losses for livestock farmers. In dairy herds, for example, there will be a negative impact on fertility and milk production where cows are affected.
"It is important that farmers have access to the best treatment options given the size of the threat and the scale of potential losses. Zanil is used widely and effectively in Ireland in the control of fluke problems, and there is no known resistance to the active ingredient oxyclozanide. With its re-introduction into the country, we believe Zanil is unique as a flukicide-only treatment that is licensed for use in lactation and in the dry period for the treatment of adult fluke in dairy cows."
Zanil is an oral drench with POM-VPS authorisation, available from both animal health suppliers and veterinary practices. Dosage rate is 3ml per 10kg bodyweight in cattle, up to a maximum of 105ml, and 4.5ml per 10kg bodyweight in sheep, up to a maximum of 20ml.
See DEFRA emerging threats reports in sheep and cattle, Q1 2013: www.defra.gov.uk/ahvla-en/files/pub-survrep-sr0113.pdf
MSD Animal Health has launched Bovilis IBR Marker Inac, an inactivated marker vaccine for use in the control of Infectious Bovine Rhinotracheitis (IBR).
The company says the new product complements Bovilis IBR Marker Live and creates a range now offering greater simplicity and additional flexibility for veterinary surgeons seeking optimum control protocols for their clients' herds.
MSD Animal Health ruminant veterinary adviser Drew McGurren MRCVS said: "Farmer compliance is an important part of any successful vaccination programme. With this extended Bovilis IBR Marker programme, farmers can now start IBR vaccination of their cattle from three months of age with a single shot primary course of Bovilis IBR Marker Live, easily followed by boosters every six months using a single dose of either Bovilis IBR Marker Live or Bovilis IBR Marker Inac. Both primary course and boosters can be administered by the same intramuscular route.
"Alternatively, Bovilis IBR Marker Inac can be administered to cattle from three months of age as a primary course of two injections four weeks apart. The programme then follows a six monthly single dose booster regime.
"The availability of Bovilis IBR Marker Inac provides a simple control option in defined farm situations, not least where an alternative to the live vaccine is preferred or required. Overall, we see this development adding convenience, ease of use and flexibility for veterinary surgeons as they work with their clients to control a significant disease threat in dairy and beef cattle in the UK."
Bovilis IBR Marker Inac is a prescription-only medicine (POM-V). The product is available from wholesalers now in 10 and 50 dose vials. For further information, contact the MSD Animal Health Veterinary Support Group on 01908 685685.
Virbac has been granted a Limited Marketing Authorisation in the UK for its Gudair vaccine, indicated for the active immunisation of sheep and goats against Mycobacterium avium subspecies paratuberculosis (MAP).
MAP is the causal organism for Johne's Disease, a chronic infection of the intestinal system for which there is no cure.
According to Virbac, Johne's Disease enters most flocks following the introduction of infected stock, often breeding rams, bought at markets without checks on disease provenance. It is then spread by the faeces of often apparently healthy animals but which can contain huge numbers of MAP. The main clinical sign is a thin ewe resulting in poor productivity followed by inevitable death. It can be passed between sheep and cattle.
Ovine Johne's Disease (OJD) in sheep is widespread in Australia where annual death rates of up to 17% have been seen in infected flocks. Virbac says that trials conducted there have demonstrated that vaccination with Gudair can reduce the number of deaths due to OJD by 90% and reduce the numbers of OJD-causing organisms excreted in sheep faeces by 90%.
Ken Sibley MRCVS, Technical Advisor at Virbac says that the number of infected flocks in the UK is unknown and the disease often remains undiagnosed: "Johne's Disease can be a significant cause of loss in infected sheep flocks because of reduced productivity and high culling rates. Vaccination provides the only possible assurance when sourcing sheep from potentially infected flocks and will help to reduce losses from the disease should a farmer inadvertently introduce sheep into an infected flock.
"Lambs identified as replacements should generally be vaccinated between 4 and 16 weeks of age, subcutaneously behind the ear. Sheep over 16 weeks of age can also be vaccinated as this will reduce shedding of organisms in infected animals while bought-in replacements can be vaccinated on arrival at the farm. Sheep require only one vaccination for their lifetime.
"Following its success in Australia, we are delighted to be able to offer Gudair to veterinary surgeons in the UK."
For further information, contact your Virbac territory manager or call: 01359 243243
BCF has released a new bovine foetal sexing quick guide as a free download from the farm animal learning section of the company's website - www.bcftechnology.com.
To help vets learn the skill of foetal sex determination with ultrasound, the guide includes:
BCF says that using ultrasound for foetal sex determination can be useful to herd management programmes: you can estimate the number of replacement heifers, further justify the culling of a cow with chronic disease (mastitis, lameness etc.) and determine pricing for a sale and/or purchase.
The guides have been created by BCF in-house vet Kimberley Palgrave who said: "The bovine foetal sexing guide was created with the aim of giving vets a few tips to help them develop confidence in foetal sex determination using ultrasound. Hopefully this guide can help people feel more assured in their technique and enable them to obtain additional information that the farmer can use in their herd management programme."